Results from the phase Ib study are expected during this September quarter.
() has received ethics approvals to advance the development of its lead drug candidate, CPAT-01, a pain control in dogs.
Phase Ib is a continuation of research into CPAT-01, an innovative cannabis-derived pain control being developed for both cats and dogs.
Set to commence this month, phase Ib of the pharmacokinetic and safety study has recruited 48 dogs for the study.
READ: CannPal Animal Therapeutics positioned in a growing animal health market
CannPal's managing director Layton Mills said: “We’re very pleased to have received ethics approval for our phase Ib study for CPAT-01.
“The speed with which CannPal has moved to the next stage of our research is indicative of our commitment to progressing our clinical development plans on time.
“We look forward to further updating the market on the results of this study, which are expected in Q3 2018.”
Study also assessing tolerability
The study design will be assessing additional pharmacokinetic and safety parameters, including tolerability at five times the estimated dose, and early dose ranging confirmation.
The company is also evaluating the cannabinoid impact on identified gene expression targets to identify underlying mechanisms of action.
